Disruption of the β2-integrin CD11d (αDβ2) gene fails to protect against experimental autoimmune encephalomyelitis

Journal of Neuroimmunology

Volumn 184, Issue 1-2, 2007, Pages 180-187

  Adams, Jillian E ^a   Webb, Matthew S ^a   Hu, Xianchen ^a   Staunton, Don ^c   Barnum, Scott R ^a,b  

^a University of Alabama at Birmingham   (United States)

^b The University of Alabama at Birmingham   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

2 integrins; Adhesion molecules; EAE; Neuroimmunology

Indexed keywords

BETA2 INTEGRIN; CYTOKINE; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CD18 ANTIGEN; GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35 55); MYELIN OLIGODENDROCYTE GLYCOPROTEIN (35-55); PEPTIDE FRAGMENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD11D GENE; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE COURSE; GENE; GENE DISRUPTION; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; KNOCKOUT MOUSE; LEUKOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; WILD TYPE; ANIMAL; C57BL MOUSE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; METABOLISM; METHODOLOGY; MOUSE MUTANT; NONPARAMETRIC TEST; PATHOLOGY; PATHOPHYSIOLOGY; SPINAL CORD; SPLEEN; TIME;

ANIMALS; ANTIGENS, CD18; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FLOW CYTOMETRY; GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; SPINAL CORD; SPLEEN; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847677223     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.12.007     Document Type: Article

References (39)

1. Archelos J.J., Previtali S.C., and Hartung H.P. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci. 22 (1999) 30-38
2. Bao F., Chen Y., Dekaban G.A., and Weaver L.C. An anti-CD11d integrin antibody reduces cyclooxygenase-2 expression and protein and DNA oxidation after spinal cord injury in rats. J. Neurochem. 90 (2004) 1194-1204
3. Barnum S.R. The complement system in demyleinating disease: new insights from transgenic and complement-deficient mice. In: Bondy S.C., and Campbell A. (Eds). Inflammatory Events in Neurodegeneration (2001), Prominent Press, Scottsdale 139-156
4. Brocke S., Piercy C., Steinman L., Weissman I.L., and Veromaa T. Antibodies to CD44 and integrin alpha4, but not l-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6896-6901
5. Bruck W. The role of macrophages in Wallerian degeneration. Brain Pathol. 7 (1997) 741-752
6. Bruck W., and Friede R.L. Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro. Acta Neuropathol. 80 (1990) 415-418
7. Bullard D.C., Hu X., Schoeb T.R., Axtell R.C., Raman C., and Barnum S.R. Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis. J. Immunol. 175 (2005) 6327-6333
8. Butcher E.C., Williams M., Youngman K., Rott L., and Briskin M. Lymphocyte trafficking and regional immunity. Adv. Immunol. 72 (1999) 209-253
9. Campbell J.J., Hedrick J., Zlotnik A., Siani M.A., Thompson D.A., and Butcher E.C. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279 (1998) 381-384
10. Cannella B., Cross A.H., and Raine C.S. Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 46 (1993) 43-55
11. Engelhardt B. Immune cell migration across the blood-brain barrier: molecular mechanisms and therapeutic targeting. Future Neurol. 1 (2006) 47-56
12. Engelhardt B., Vestweber D., Hallmann R., and Schulz M. E- and P-selectin are not involved in the recruitment of inflammatory cells across the blood-brain barrier in experimental autoimmune encephalomyelitis. Blood 90 (1997) 4459-4472
13. Engelhardt B., Laschinger M., Schulz M., Samulowitz U., Vestweber D., and Hoch G. The development of experimental autoimmune encephalomyelitis in the mouse requires alpha4-integrin but not alpha4beta7-integrin. J. Clin. Invest. 102 (1998) 2096-2105
14. Engelhardt B., Kempe B., Merfeld-Clauss S., Laschinger M., Furie B., Wild M.K., and Vestweber D. P-selectin glycoprotein ligand 1 is not required for the development of experimental autoimmune encephalomyelitis in SJL and C57BL/6 mice. J. Immunol. 175 (2005) 1267-1275
15. Fagerholm S.C., Hilden T.J., and Gahmberg C.G. P marks the spot: site-specific integrin phosphorylation regulates molecular interactions. Trends Biochem. Sci. 29 (2004) 504-512
16. Gordon E.J., Myers K.J., Dougherty J.P., Rosen H., and Ron Y. Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 62 (1995) 153-160
17. Gris D., Marsh D.R., Oatway M.A., Chen Y., Hamilton E.F., Dekaban G.A., and Weaver L.C. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J. Neurosci. 24 (2004) 4043-4051
18. Gris D., Marsh D.R., Dekaban G.A., and Weaver L.C. Comparison of effects of methylprednisolone and anti-CD11d antibody treatments on autonomic dysreflexia after spinal cord injury. Exp. Neurol. 194 (2005) 541-549
19. Huitinga I., Damoiseaux J.G., Dopp E.A., and Dijkstra C.D. Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in Lewis rats. Eur. J. Immunol. 23 (1993) 709-715
20. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 110 (2002) 673-687
21. Kent S.J., Karlik S.J., Cannon C., Hines D.K., Yednock T.A., Fritz L.C., and Horner H.C. A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58 (1995) 1-10
22. Mabon P.J., Weaver L.C., and Dekaban G.A. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166 (2000) 52-64
23. Mayadas T.N., and Cullere X. Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol. 26 (2005) 388-395
24. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., and O'Connor P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003) 15-23
25. Myers K.J., Witchell D.R., Graham M.J., Koo S., Butler M., and Condon T.P. Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis. J. Neuroimmunol. 160 (2005) 12-24
26. Nataf S., Carroll S.L., Wetsel R.A., Szalai A.J., and Barnum S.R. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J. Immunol. 165 (2000) 5867-5873
27. Osmers I., Bullard D.C., and Barnum S.R. PSGL-1 is not required for development of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 166 (2005) 193-196
28. 2+. Proc. Natl. Acad. Sci. 87 (1990) 9472-9476
29. Saville L.R., Pospisil C.H., Mawhinney L.A., Bao F., Simedrea F.C., Peters A.A., O'Connell P.J., Weaver L.C., and Dekaban G.A. A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment. J. Neuroimmunol. 156 (2004) 42-57
30. Shanley T.P., Warner R.L., Crouch L.D., Dietsch G.N., Clark D.L., O'Brien M.M., Gallatin W.M., and Ward P.A. Requirements for alpha d in IgG immune complex-induced rat lung injury. J. Immunol. 160 (1998) 1014-1020
31. Smith M.E. Phagocytosis of myelin in demyelinative disease: a review. Neurochem. Res. 24 (1999) 261-268
32. *. Annu. Rev. Immunol. 23 (2005) 683-747
33. Szalai A.J., Nataf S., Hu X.Z., and Barnum S.R. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J. Immunol. 168 (2002) 5792-5797
34. Underhill D.M., and Ozinsky A. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20 (2002) 825-852
35. von Andrian U.H., and Mackay C.R. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343 (2000) 1020-1034
36. Welsh C.T., Rose J.W., Hill K.E., and Townsend J.J. Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1 alpha. J. Neuroimmunol. 43 (1993) 161-167
37. Willenborg D.O., Staykova M.A., and Miyasaka M. Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J. Immunol. 157 (1996) 1973-1980
38. Wu H., Rodgers J.R., Perrard X.Y., Perrard J.L., Prince J.E., Abe Y., Davis B.K., Dietsch G., Smith C.W., and Ballantyne C.M. Deficiency of CD11b or CD11d results in reduced staphylococcal enterotoxin-induced T cell response and T cell phenotypic changes. J. Immunol. 173 (2004) 297-306
39. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., and Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 356 (1992) 63-66